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Abstract 
Background: A growing body of literature suggests etiological overlap between Ehlers-Danlos syndrome 
(EDS)/hypermobility spectrum disorders (HSD) and some cases of autism, although this relationship is poorly delineated. In 
addition, immune, autonomic, and endocrine dysregulation are reported in both conditions and may be relevant to their 
respective etiologies.  
Aims: To study symptom overlap in these two comorbid spectrum conditions.  
Methods and Procedures: We surveyed 702 adults aged 25+ years on a variety of EDS/HSD-related health topics, 
comparing individuals with EDS/HSD, autism, and unaffected controls.  
Outcomes and Results: The autism group reported similar though less severe symptomology as the EDS/HSD group, 
especially in areas of immune/autonomic/endocrine dysregulation, connective tissue abnormalities (i.e., skin, 
bruising/bleeding), and chronic pain. EDS/HSD mothers with autistic children reported more immune symptoms than 
EDS/HSD mothers without, suggesting the maternal immune system could play a heritable role in these conditions (p = 
0.0119).  
Conclusions and Implications: These data suggest that EDS/HSD and autism share aspects of 
immune/autonomic/endocrine dysregulation, pain, and some tissue fragility, which is typically more severe in the former. This 
overlap, as well as documented comorbidity, suggests some forms of autism may be hereditary connective tissue disorders 
(HCTD). 
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1. Introduction 
At face value, Ehlers-Danlos syndrome 
(EDS)/hypermobility spectrum disorders (HSD) 
and autism appear to have little in common. Though 
autism can be accompanied by a variety of medical 
issues, it is first and foremost defined as a behavioral 
syndrome. In contrast, EDS/HSD is a group of 
hereditary connective tissue disorders (HCTD) 
believed to be due to a deficiency in collagen 
fibrillogenesis. Therefore, symptoms in these 
conditions stem largely from connective tissue 
dysplasias (joint instability, pain, skin elasticity, 
tissue fragility, etc.). 
Early evidence suggests that autism and EDS/HSD 
overlap comorbidly (Casanova et al., 2018; Baeza-
Velasco et al., 2015). Although a number of case 
studies have been published since the 1980s, a more 
recent nationwide study from Sweden indicates that 
approximately 3% of individuals with EDS have an 
autism diagnosis (Fehlow & Tennstedt, 1985; Sieg, 
1992; Fehlow et al., 1993; Takei et al., 2011; 
Cederlöf et al., 2016). However, the high 
preponderance of women with EDS/HSD and the 
recognition that autism is often under-diagnosed in 
female demographics suggests this could be an 
underestimate of comorbidity (Gould & Ashton-
Smith, 2011). Up-to-date prevalence estimates of 
hypermobile EDS (hEDS), the most common form 
of EDS, are also currently lacking, as are estimates 
on the new diagnostic entity, hypermobility 
spectrum disorders (HSD).  
Although etiological mechanisms underlying the 
co-occurrence of EDS/HSD and autism are poorly 
understood, we know for instance that the 
extracellular matrix (ECM) plays foundational roles 
in brain development, providing scaffolds for 
proliferating and migrating neurons, as well as 
helping to maintain synaptic contacts throughout life 
(Mercier et al., 2002; Thomas & Steindler, 1996; 
Sheen et al., 2005; Su et al., 2010). The immune 
system has also been implicated in autism’s etiology 
and is a system that is significantly dysregulated in 
EDS/HSD and other hereditary connective tissue 
disorders (Seneviratne, 2017; Felgentreff et al., 
2014; Patterson, 2011). In addition, autonomic 
disorders have been reported in both these groups 
and could be a cause or consequence of immune 
dysregulation (Sokhadze et al., 2018; Cheung & 
Vadas, 2015; Czura & Tracey, 2005; Roth et al., 
2004; Bienenstock et al., 1987). For these reasons, 
we have elected to study self-reported immune and 
autonomic symptom frequency in the adult 
EDS/HSD and autism populations as compared to 
controls. We also investigate the frequency in 
autism of other symptoms typically associated with 
EDS/HSD, including items such as chronic pain 
and tissue fragility. 
2. Material and Methods 
2.1 Study Population 
Approximately 99% of respondents answered the 
survey on behalf of themselves, rather than as legal 
guardians of adult wards. Our study sample was 
composed of English-speaking adults aged 25 years 
or older [N = 702]. (For basic demographics, see 
Table 1. Note that specific data on socioeconomic 
status and educational attainment levels were not 
recorded.) 
 
Table 1 
 Sex, age, racial descent, and country of residence according to group. Figures presented represent diagnostically 
“pure” (i.e., non-mixed) clinical and control groups. 
 
Demographics 
 
EDS/HSD 
(N = 268) 
Autism 
(N = 152) 
CON 
(N = 147) 
Sex Male 
 
Female 
 
Other 
6% 
 
92.5% 
 
1.5% 
34.9% 
 
58.6% 
 
6.6% 
31.8% 
 
66.2% 
 
2% 
Age Average 35.9 ± 9.7 
years 
37.6 ± 10.4 
years 
33.0 ± 10.2 years 
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Descent Sub-saharan 
African 
 
Middle Eastern 
& Northern 
African 
 
East Asian & 
Native 
American 
 
South Asian 
 
Northwestern 
European 
 
Eastern 
European 
 
Southern 
European 
 
2.6% 
 
 
1.5% 
 
 
 
 
13.8% 
 
 
1.1% 
 
85.4% 
 
 
23.5% 
 
 
17.5% 
2% 
 
 
0.7% 
 
 
 
 
11.1% 
 
 
0% 
 
87% 
 
 
17.6% 
 
 
8.5% 
0.7% 
 
 
2% 
 
 
 
 
8.1% 
 
 
0% 
 
78.4% 
 
 
27% 
 
 
17.6% 
Country of Residence Australia/New 
Zealand 
 
Bahrain 
 
Belgium 
 
Brazil 
 
Canada 
 
Democratic 
Republic of 
Congo 
 
Denmark 
 
Dominican 
Republic 
 
Finland 
 
France 
 
Germany 
 
Iceland 
 
4.9% 
 
 
0% 
 
0.4% 
 
0% 
 
9.7% 
 
0% 
 
 
 
0.7% 
 
0% 
 
 
0% 
 
0% 
 
0.4% 
 
0% 
 
8.6% 
 
 
0% 
 
1.3% 
 
0% 
 
5.3% 
 
0% 
 
 
 
1.3% 
 
0% 
 
 
0% 
 
3.3% 
 
0.7% 
 
2% 
 
2% 
 
 
0.7% 
 
0% 
 
0.7% 
 
10.1% 
 
0.7% 
 
 
 
0% 
 
0.7% 
 
 
0.7% 
 
0% 
 
2.7% 
 
0% 
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Israel 
 
Italy 
 
Netherlands 
 
Norway 
 
Poland 
 
Russia 
 
Singapore 
 
South Africa 
 
Spain 
 
Sweden 
 
United Kingdom 
 
United States of 
America 
 
Uzbekistan 
0% 
 
0% 
 
0% 
 
0% 
 
0.4% 
 
0.4% 
 
0.4% 
 
0.4% 
 
0% 
 
0.4% 
 
9.3% 
 
71.3% 
 
 
0.4% 
0% 
 
0% 
 
2% 
 
0.7% 
 
0% 
 
0.7% 
 
0% 
 
0.7% 
 
0.7% 
 
1.3% 
 
25% 
 
45.4% 
 
 
0% 
0.7% 
 
0.7% 
 
0% 
 
0.7% 
 
1.4% 
 
1.4% 
 
0% 
 
0.7% 
 
0% 
 
0% 
 
11.5% 
 
61.5% 
 
 
0.7% 
 
Our sample was divided into three major groups: 1) 
individuals reporting diagnosis of EDS or the now-
obsolete joint hypermobility syndrome (JHS), with 
or without an additional diagnosis of autism [N = 
403]; 2) individuals reporting a diagnosis of autism 
but without a diagnosis of EDS/HSD [N = 152]; and 
3) individuals reporting neither EDS/HSD or autism 
(diagnosed or suspected) or with a 1st degree relative 
with any of these diagnoses [N = 147]. Individuals 
who were under the age of 25 or who had a 1st 
degree relative with EDS/HSD or autism and didn’t 
themselves have either of these conditions were 
removed from the study. (Unfortunately, family 
members of those with EDS/HSD or autism did not 
form large enough subgroups to be studied 
individually.) In addition, individuals who 
suspected a diagnosis of EDS/HSD but did not 
report a diagnosis were also removed from the 
study. For most analyses, the data of individuals 
with EDS/HSD diagnoses who suspected they had 
autism but were undiagnosed were not used, with a 
few exceptions such as the analyses on maternal 
heredity and EDS/HSD within-group comparisons. 
For analyses in which sex was controlled as a 
potential confounding variable, individuals who did 
not identify as either male or female were removed 
from the data pool. 
The majority (74%) of EDS/HSD respondents 
reported a diagnosis of hEDS [N = 294]. 
Meanwhile, 9% of EDS/HSD respondents reported 
a diagnosis of classic EDS (cEDS) [N = 37], 3% 
reported a diagnosis of vascular EDS (vEDS) [N = 
12], and 6% reported another form of EDS not 
easily categorized in this study. Nine percent of 
EDS/HSD respondents reported the older diagnosis 
of JHS, which would nowadays either be diagnosed 
as generalized hypermobility spectrum disorder (G-
HSD) or asymptomatic generalized joint 
hypermobility (A-GJH). In this case, however, all 
JHS respondents reported significant 
musculoskeletal pain and instability, indicating that 
they are symptomatic and would therefore fall under 
the G-HSD umbrella were they to be reassessed at 
present. 
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2.2 Survey 
This survey was approved by the Institutional 
Review Board (IRB) of the Greenville Health 
System (GHS) (ID: Pro00073030). It was an 
extension of a previous survey designed by our 
group, partly based off of the Vanderbilt Autonomic 
Dysfunction Center Medical Questionnaire and a 
series of surveys utilized by the Autism Research 
Institute (see Casanova et al., 2018; Vanderbilt 
Autonomic Dysfunction Center, 2018).  
The survey was built on and hosted by the website, 
SurveyGizmo, and was advertised on a variety of 
websites, including Ehlers-Danlos-specific 
Facebook and reddit groups, Wrong Planet forums, 
and Survey Tandem. For websites such as reddit 
and Survey Tandem, requirements for posting 
research advertisements were followed according to 
the rules of each respective site (see Supplementary 
File 1 for survey). For forums and Facebook groups, 
the administrative teams of these webgroups were 
approached and asked for permission in order to 
post the study advertisement. Following 
administrator approval, the primary author posted 
the study advert.  
The survey weblink 
(http://www.surveygizmo.com/s3/3420093/Expan
ding-Our-Understanding-of-Symptoms-
Associated-with-Ehlers-Danlos-Syndromes) led to 
a description of the study, including potential 
risks/benefits and expectations, investigator contact 
information, and a waiver of consent. The survey 
was available and data was collected for six months. 
Survey questions covered a wide variety of medical 
and health issues, many of which have been 
referenced in the EDS-related literature as well as 
our own previous work (Casanova et al., 2018). 
Some of the major systems of interest include the 
immune (Fig. 1a), endocrine, and autonomic 
nervous systems, which have previously been 
implicated in both EDS/HSD and autism 
(Seneviratne et al., 2017; Kushki et al., 2013; De 
Wandele et al., 2014; Careaga et al., 2017; 
Ingudomnukul et al., 2007; Castori et al., 2012). In 
addition, we also asked about other symptoms 
associated with EDS/HSD, such as musculoskeletal 
pain and instability, dermatological issues (elasticity, 
scarring, wound healing), vascular complications, 
and other forms of chronic pain. Some psychiatric 
comorbidities were also covered in the survey.  
2.3 Statistical Analyses 
Group comparisons for binary outcomes were 
compared using logistic regression analysis. When 
a group proportion for a particular symptom was 
zero or very small, odds ratio confidence intervals 
including that group were unbounded (upper bound 
was infinity) and were not interpreted. Multiple 
comparisons within a particular symptom were 
adjusted using a false discovery rate p-value 
adjustment. For comparing symptom sums among 
the groups, a Kruskal-Wallis test was used. Follow-
up analyses to compare groups pairwise were 
considered using the Wilcoxon Rank Sum Test. A 
significance level of 0.05 was used for all tests of 
significance. 
3. Results 
3.1 The Immune, Endocrine, & Autonomic 
Nervous Systems 
In agreement with the general literature, we found 
that the distributions of immune-mediated and 
autonomic symptoms differed across our control 
group by gender (women > men) [W = 2826.5-
2843, p = 0.021-0.024] (Oertelt, 2012; Lambrecht et 
al., 2010). A similar gender disparity was also 
present within each of our clinical groups, although 
the number of men within the EDS/HSD group (N 
= 16) was comparatively small given the extreme 
sex-skewing of the condition [W = 2826.5-3018, p 
< 0.001-0.016] (Hamonet & Brock, 2015). Using a 
series of Kruskal-Wallis rank sum tests, we found 
that immune-mediated and autonomic symptoms 
were also staggered according to group: individuals 
with EDS/HSD reported the most symptoms, 
followed by those with autism, and finally controls 
[X2 = 11.782-217.57, p < 0.0001-0.003] (Fig. 1b,c). 
In contrast, endocrine-mediated symptoms 
primarily differed in females by group (EDS/HSD 
> autism > controls) [X2 = 55.792, p < 0.0001] (Fig. 
1d) but did not differ significantly in males [X2 = 
1.6871, p = 0.4302]. This was due to the fact that 
female-specific endocrine disorders (e.g., 
endometriosis, menorrhagia) were the major drivers 
of group divergence in this study. (See 
Supplementary File1, Table 1 for full results. 
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Figure 1:  Immune, endocrine, and autonomic dysregulation. 
(A) Pie chart listing the various immune-mediated symptoms investigated in this study. (Slices are not proportional to rate of 
occurrence in this study.) (B-D) Immune-, autonomic-, and endocrine-mediated symptoms in women according to group. 
 
When we looked at EDS/HSD subtypes, we found 
that their immune, autonomic, and endocrine 
profiles were more similar than not. While we were 
unable to investigate all EDS subtypes due to their 
rarity, we were nevertheless able to compare hEDS, 
cEDS, vEDS, and JHS (the latter a diagnosis which 
many respondents retain due to the recency of 
nosological changes) (Castori et al., 2017). There 
was a significant difference in the distribution of 
both immune-mediated and autonomic symptoms 
according to EDS/HSD subtype [X2 = 13.205-
16.234, p = 0.0027-0.0103], though endocrine 
symptoms did not appear to differ [X2 = 4.9388, p = 
0.2936]. Immunologically and autonomically, JHS 
is less severe than the other EDS subtypes; however, 
symptomologically JHS is more similar to EDS 
than to either the autism or control groups, 
suggesting a difference in severity rather than 
necessarily one of kind (Supplementary File 2, 
Table 2). 
There is a small but growing literature that suggests 
an etiological overlap between EDS/HSD and 
autism (Casanova et al., 2018; Baeza-Velasco et al., 
2015). While we are unable to estimate true 
comorbidity rates in this study due to the ways in 
which respondents were recruited (potential bias), 
we will nevertheless briefly describe our EDS/HSD 
sample. Approximately 12% of EDS/HSD 
participants reported a dual diagnosis of autism. 
Meanwhile, an additional 21% of EDS/HSD 
respondents reported that they suspected they had 
autism or fell within the broader phenotype. 
Therefore, up to one-third of our EDS/HSD sample 
may have been on or near the autism spectrum. 
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We also found that a large percentage of EDS/HSD 
mothers reported having autistic children (20%), a 
figure that was almost identical to that seen in 
mothers with autism (19%) (Fig. 2a). Although the 
log odds did not significantly differ between the two 
groups [X2 = 1.1322, p = 0.5677], these results must 
be interpreted with extreme caution due to the 
potentially biased manner in which respondents 
were recruited. Interestingly, rates of autism in the 
offspring did not significantly differ across the 
different maternal EDS/HSD subgroups, which 
tentatively suggests that autism may be associated 
with various forms of EDS/HSD [X2 = 0.4807, p = 
0.4881] (Fig. 2b). Further research is desperately 
needed to determine both autism comorbidity and 
inheritance rates in these families. 
 
Figure 2: Autism and EDS/HSD in the Offspring 
(A) Reported rates of autism diagnosis in children of mothers with clinical syndromes of interest. (B) Reported rates of 
EDS/HSD diagnosis in children of mothers with clinical syndromes of interest. (C) Rates of immune-mediated symptoms in 
mothers with EDS/HSD in relation to the child’s autism diagnosis. (D) Rates of immune-mediated symptoms in mothers with 
EDS/HSD in relation to the child’s EDS/HSD diagnosis. 
 
More intriguingly, the distribution of immune-
mediated symptoms in EDS/HSD mothers who 
had autistic children significantly differed from 
those with non-autistic children, with the former 
reporting on average 28% more symptoms than the 
latter [mean = 10.4 symptoms (Sx) > 8.1 Sx, t = -
2.51, p = 0.015] (Fig. 2c). Surprisingly, the 
distribution of immune symptoms between 
EDS/HSD mothers who had EDS/HSD children 
and those without also significantly differed, with 
the former reporting about 25% more symptoms 
than the latter (mean = 9.6 Sx > 7.7 Sx) [W = 1496, 
Medical Aspects of Disability 
___________________________________________________________________________ 
Journal for ReAttach Therapy and Developmental Diversities 2020 Jan 22; 2(2):82-95.                                   89 
p = 0.0145] (Fig. 2d). However, neither of these 
groups experienced significantly increased 
autonomic or endocrine-mediated symptoms [W = 
1321-1760, p = 0.0945-0.2356] (1) (see 
Supplementary File 2, Fig. 1). Therefore, the 
etiologies of both EDS/HSD and autism seem to 
share links with the maternal immune system in 
particular (Garay et al., 2013; McDougle, 2018). 
(For more results involving immune dysregulation, 
see Supplementary File 2, Fig. 2-3.) 
 
 
Figure 3: EDS/HSD-associated Symptoms 
Reported rates of hypermobility, dislocations/subluxations, chronic fatigue, clumsiness, chronic pain, and skin fragility 
according to group. 
 
3.2 Other Ehlers-Danlos-related Symptomology 
We collected data on additional symptomology 
associated with EDS/HSD, in order to compare 
relative frequencies across groups (Table 2). (Due to 
small numbers within the male EDS/HSD 
subgroup, all results reported here concern females 
only unless otherwise stated.) In terms of 
hypermobility, joint dislocations/subluxations, skin 
fragility, chronic pain, general clumsiness, and 
chronic fatigue, as expected the EDS/HSD group 
Casanova, E. L., et al.       Immune/Autonomic/Endocrine Dysregulation in EDS/HSD and Autism 
___________________________________________________________________________
90                                                                                                                                                    https://jrtdd.com 
 
reported significantly more symptoms compared to 
both the autistic and control groups [all p > 0.001-
0.0022] (Fig. 3). The autism group likewise differed 
from controls in terms of clumsiness, chronic pain, 
chronic fatigue, and skin fragility [all p ≤ 0.002], but 
did not differ as to hypermobility and 
dislocations/subluxations [all p = 0.136-0.6568]. 
Males with autism also significantly differed from 
control males in the same regards [all p = 0.028-
0.042]. These data suggest that some forms of 
chronic pain, tissue fragility, and fatigue may be of 
concern even in autism unassociated with 
EDS/HSD. 
 
Table 2 
EDS-associated symptom frequency by group 
  
EDS/HSD Autism CON Respondents 
used in 
analysis 
Head Injury 20% 8% 9% females only 
Migraine 80% 52% 42% females only 
Non-migraine headache 47% 11% 15% females only 
Bruise Easily 87% 46% 32% females only 
Difficult-to-control bleeds 29% 1% 2% females only 
Scars easily 70% 27% 14% females only 
Cigarette paper scars 46% 1% 0% females only 
Elastic skin 47% 6% 0% females only 
Slow wound healing 66% 19% 5% females only 
Clumsy 66% 52% 19% females only 
Joint pain 95% 26% 16% females only 
Muscle pain 82% 21% 7% females only 
Arthritis 29% 12% 6% females only 
Fibromyalgia 29% 10% 2% females only 
Temporomandibular joint 
(TMJ) pain 
64% 24% 9% females only 
Neuropathy 36% 7% 4% females only 
Joint 
dislocations/subluxations 
89% 8% 3% females only 
Foot problems 90% 42% 33% females only 
Crooked/crowded teeth 
(current or historicalf) 
78% 69% 53% females only 
Scoliosis 36% 15% 11% females only 
Kyphosis 13% 2% 2% females only 
Missing/extra bones 17% 8% 5% females only 
Chiari malformation 6% 0% 0% females only 
Prematurity (self) 13% 16% 12% females only 
Prematurity (child) 25% 9% 24% mothers only 
Preeclampsia 26% 9% 26% mothers only 
Gestational diabetes 11% 6% 18% mothers only 
Uterine prolapse 13% 3% 0% mothers only 
Miltral valve prolapse 14% 3% 2% females only 
Venous arterial dissection 1% 0% 0% females only 
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Cavernous sinus fistula 0% 0% 0% females only 
Aneurysm 2% 0% 1% females only 
Brain hemorrhage 0% 1% 0% females only 
Stroke 1% 1% 0% females only 
Other vascular 
complications 
15% 0% 3% females only 
Myopia 61% 62% 45% females only 
Eye strain 52% 26% 5% females only 
Retinal detachment 3% 1% 0% females only 
Ptosis 21% 4% 2% females only 
Blue/gray sclera 24% 1% 0% females only 
Astigmatism 64% 54% 37% females only 
Keratoconus 3% 1% 0% females only 
Chronic dry eye 36% 9% 10% females only 
Strabismus 11% 7% 4% females only 
All cancer (self) 5% 4% 2% females only 
Cancer under 35 4% 0% 1% females only 
Epilepsy (self) 4% 6% 0% females only 
Epilepsy (relatives) 8% 5% 1% males and 
females 
ADHD 20% 19% 7% females only 
Anxiety disorder 42% 42% 26% females only 
Mood disorder 29% 47% 20% females only 
PTSD 13% 8% 3% females only 
Adverse reaction to 
vaccination 
28% 18% 6% females only 
Mild immunodeficiency 24% 9% 8% females only 
 
As expected, we also found that the distribution of 
vascular complications, such as strokes, aneurysms, 
and hemorrhages, significantly differed across 
groups and were far more common in the 
EDS/HSD group (21%), while they did not differ 
between autism and controls (2% vs. 4%) [X2 = 
24.809, p < 0.001]. Likewise, the log odds of head 
injuries and proportions of Chiari malformations 
differed significantly across groups, and were 
unusually high in the EDS/HSD group, findings 
which have previously been reported in the EDS 
literature [head injury: X2 = 19.086, p < 0.0001; 
Chiari: Fisher’s Exact Test p = 0.002] (Hamonet et 
al., 2016; Malfait et al., 2010; Castori et al., 2010) 
(Table 2).  
3.3 Neurodevelopmental and Psychiatric 
Conditions 
Both autism and EDS/HSD are sometimes 
associated with other neurodevelopmental and/or 
psychiatric conditions. When asked to report on 
comorbid diagnoses of attention deficit/ 
hyperactivity disorder (ADHD), anxiety disorders, 
mood disorders, and post traumatic stress disorder 
(PTSD), we found that reports significantly differed 
by group, although this was largely driven by 
clinical groups versus controls [X2 = 10.6538-
16.402, p < 0.0066-0.0138]. In fact, when analyzed 
individually, EDS/HSD and autism did not 
significantly differ from one another, although 
individuals with autism did report more mood 
disorders than those with EDS/HSD (47% vs. 
29%). This suggests that neurodevelopmental and 
psychiatric comorbidities are similar across our two 
clinical groups and that some features of EDS/HSD 
may be neurodevelopmental in origin. We also 
found that log odds of comorbidity did not differ 
significantly across the EDS/HSD subgroups, 
indicating that they are all similarly affected and that 
neurodevelopmental and psychiatric conditions do 
not cluster within select forms of EDS [X2 = 1.0026-
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3.017, all adjusted p = 0.8006] (Bulbena-Cabré & 
Bulbena, 2018). 
4. Discussion 
This study attempted to investigate a variety of 
health issues across EDS/HSD, autism, and 
controls. Much of the survey design was guided by 
previous EDS/HSD research (Casanova et al., 
2018). Given the apparent (though still poorly 
delineated) comorbidity between EDS/HSD and 
autism, we felt it was important to determine to what 
extent EDS/HSD issues affect the autism spectrum.  
In summarizing the data presented here, those with 
autism (without EDS/HSD) appear to have 
significant issues concerning immune/autonomic/ 
endocrine dysregulation, connective tissue (skin) 
durability, chronic pain, and fatigue. In addition, 
autistic women experience more endocrine 
disorders than sex-matched controls. All of these 
symptoms appear to be less extreme than those seen 
in individuals with EDS/HSD, which may share 
striking comorbidity with autism. In contrast, issues 
such as hypermobility, dislocations/subluxations, 
vascular complications, chiari malformation, and 
head injury all appear to be largely specific to the 
EDS/HSD diagnosis. 
Autism seems to occur alongside EDS/HSD with 
some frequency, although we cannot estimate 
comorbidity rates in this study due to potential 
recruitment bias. There is also evidence to suggest 
that maternal EDS/HSD could be a risk factor for 
the development of autism and EDS/HSD in the 
offspring, although, once again, more research is 
needed to address this possibility. In particular, our 
data indicate that the maternal immune system may 
play a regulatory role, a finding that echoes the 
general autism literature (Patterson, 2011).  
4.1 Limitations 
As with all survey studies, the veracity and 
applicability of our data is a reflection of the 
reliability of reporting of our respondents. Because 
our findings generally agree with those previously 
reported throughout the EDS/HSD and autism 
literature, this lends support to the data and the 
conclusions presented here, although clearly more 
clinical research is needed (Seneviratne et al., 2017; 
Kushki et al., 2013; De Wandele et al., 2014; 
Careaga et al., 2017; Ingudomnukul et al., 2007).  
Recent changes in hEDS nosology also make it 
challenging to accurately assign participants to the 
EDS versus HSD subheadings as many will have 
received diagnoses prior to the latest diagnostic 
update. For this reason all respondents reporting a 
form of EDS, G-HSD, or JHS have been subsumed 
under the general “EDS/HSD” heading for most 
analyses. Given evidence of their relatedness both in 
this and previous studies, as well as the 
musculoskeletal impairment reported by our sample 
of respondents, we feel such a compilation is 
justified. 
Another limitation of some of our EDS/HSD data 
involves small sample sizes. While the number of 
hEDS participants was substantial, the rarer forms 
of EDS, such as vEDS, were especially small in 
number and it is therefore difficult to draw 
conclusions about their responses, except to say that 
with current numbers the vEDS data do not appear 
to differ substantially from the other EDS/HSD 
subgroups. While this must be interpreted 
cautiously, it does suggest that people with vEDS 
experience many of the same secondary clinical 
phenotypes as the more common forms of 
EDS/HSD, reinforcing concepts of a common 
Ehlers-Danlos syndrome despite genetic 
heterogeneity. Further research will continue to test 
this possibility. 
Finally, as has been mentioned previously, we 
cannot address comorbidity and inheritance rates 
between EDS/HSD and autism due to the ways in 
which participants were recruited. It is therefore 
possible and perhaps likely that individuals with 
comorbid EDS/HSD and autism diagnoses or 
EDS/HSD parents with autistic children were more 
drawn to participate. For these reasons we have 
simply described our study population qualitatively.  
5. Conclusions 
Although we cannot estimate comorbidity rates, the 
data presented here suggest at least a small portion 
of the autism spectrum may fulfill criteria for 
EDS/HSD. Prevalence rates of EDS are poorly 
researched, with current data estimating the 
condition affects 1:5,000 individuals. However, 
current clinical expertise suggests this is an 
underestimation and that it is far more common 
(EDS Society, 2018). In summary, these data 
suggest an intriguing possibility that some forms of 
autism are HCTDs. Our laboratory continues to 
work to address this possibility and to help improve 
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the lives of those with these spectrum conditions 
dealing with chronic illness. 
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